Indications: Solid tumors / AMD
PMC-403 is a monoclonal antibody that targets the human Tie2 that regulate the angiogenesis and vessel maturation in endothelial cells.
Mechanism of action / Target
PMC-403 binds to TIE2 expressing endothelial cells that normalize VEGF-induced tumor vessel leakage in the tumor microenvironment (TME).
PMC-403 was tested in various vessel-related disease such as age-related macular degeneration(AMD), diabetic retinopathy, and cancer. In these models, significant vessel normalizing effect was found which suggest versatile use in wide indications. GLP-toxicity study needed for the IND application will be completed in the near future.
2F, Research Building 2, 70,
Yuseong-daero 1689 beon-gil,
Yuseong-gu, Daejeon, 34047, Republic of Korea
R&D Center +82-42-861-2017
Investor Relations +70-4294-6097
COPYRIGHT BY PharmAbcine Inc.
ALL RIGHTS RESERVE